Want to see KR:214390 full AI Analyst Report?
Kyongbo Pharmaceutical Co., Ltd. (214390) Ratios
Kyongbo Pharmaceutical Co., Ltd. Ratios
KR:214390's free cash flow for Q2 2026 was $-16.51B. For the 2026 fiscal year, KR:214390's free cash flow was decreased by $-15.94B and operating cash flow was $-565.17M. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 1.08 | 1.15 | 1.15 | 1.22 | 1.25 |
| Quick Ratio | 0.53 | 0.46 | 0.55 | 0.62 | 0.60 |
| Cash Ratio | 0.05 | 0.03 | 0.04 | 0.07 | 0.05 |
| Solvency Ratio | 0.08 | 0.12 | 0.12 | 0.13 | 0.06 |
| Operating Cash Flow Ratio | 0.05 | 0.00 | 0.04 | 0.11 | 0.20 |
| Short-Term Operating Cash Flow Coverage | 0.07 | 0.00 | 0.07 | 0.16 | 0.32 |
| Net Current Asset Value | $ -14.66B | $ 14.21B | $ 13.98B | $ 19.48B | $ 19.89B |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.40 | 0.32 | 0.29 | 0.27 | 0.24 |
| Debt-to-Equity Ratio | 0.87 | 0.63 | 0.53 | 0.45 | 0.39 |
| Debt-to-Capital Ratio | 0.47 | 0.38 | 0.34 | 0.31 | 0.28 |
| Long-Term Debt-to-Capital Ratio | 0.14 | 0.01 | 0.00 | 0.00 | 0.00 |
| Financial Leverage Ratio | 2.20 | 1.94 | 1.84 | 1.67 | 1.63 |
| Debt Service Coverage Ratio | 0.16 | 0.23 | 0.24 | 0.21 | 0.12 |
| Interest Coverage Ratio | 0.82 | 2.44 | 1.63 | 0.83 | -5.63 |
| Debt to Market Cap | 0.91 | 0.61 | 0.36 | 0.26 | 0.22 |
| Interest Debt Per Share | 5485.76 | 4003.94 | 3318.58 | 2768.38 | 2416.14 |
| Net Debt to EBITDA | 7.14 | 4.04 | 4.14 | 4.55 | 12.42 |
| Profitability Margins | |||||
| Gross Profit Margin | 37.04% | 34.55% | 29.15% | 22.63% | 19.42% |
| EBIT Margin | 1.33% | 3.85% | 2.58% | 0.54% | -5.01% |
| EBITDA Margin | 6.33% | 9.05% | 7.97% | 6.51% | 2.47% |
| Operating Profit Margin | 1.33% | 4.38% | 2.56% | 0.71% | -3.88% |
| Pretax Profit Margin | 0.17% | 2.06% | 1.00% | -0.31% | -5.82% |
| Net Profit Margin | 0.07% | 1.94% | 1.37% | 0.31% | -4.39% |
| Continuous Operations Profit Margin | 0.07% | 1.94% | 1.37% | 0.31% | -4.39% |
| Net Income Per EBT | 40.56% | 94.62% | 136.95% | -99.31% | 75.46% |
| EBT Per EBIT | 12.77% | 46.90% | 39.17% | -44.15% | 149.93% |
| Return on Assets (ROA) | 0.06% | 1.63% | 1.12% | 0.25% | -3.16% |
| Return on Equity (ROE) | 0.13% | 3.17% | 2.06% | 0.42% | -5.14% |
| Return on Capital Employed (ROCE) | 2.05% | 6.91% | 3.75% | 0.96% | -4.47% |
| Return on Invested Capital (ROIC) | 0.52% | 4.09% | 2.49% | -0.66% | -2.45% |
| Return on Tangible Assets | 0.06% | 1.66% | 1.13% | 0.26% | -3.21% |
| Earnings Yield | 0.13% | 3.12% | 1.47% | 0.25% | -2.92% |
| Efficiency Ratios | |||||
| Receivables Turnover | 3.96 | 4.56 | 3.85 | 3.86 | 3.64 |
| Payables Turnover | 11.26 | 10.44 | 6.73 | 10.30 | 8.25 |
| Inventory Turnover | 2.05 | 1.72 | 2.17 | 2.64 | 2.35 |
| Fixed Asset Turnover | 2.06 | 2.39 | 2.25 | 2.09 | 1.78 |
| Asset Turnover | 0.83 | 0.84 | 0.81 | 0.82 | 0.72 |
| Working Capital Turnover Ratio | 16.95 | 12.92 | 11.27 | 9.11 | 5.11 |
| Cash Conversion Cycle | 237.41 | 256.85 | 208.78 | 197.18 | 211.64 |
| Days of Sales Outstanding | 92.08 | 80.04 | 94.74 | 94.54 | 100.32 |
| Days of Inventory Outstanding | 177.75 | 211.76 | 168.27 | 138.08 | 155.58 |
| Days of Payables Outstanding | 32.42 | 34.95 | 54.23 | 35.44 | 44.25 |
| Operating Cycle | 269.83 | 291.80 | 263.01 | 232.61 | 255.90 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | 312.30 | 6.24 | 202.63 | 423.59 | 751.57 |
| Free Cash Flow Per Share | -1427.67 | -544.86 | -252.35 | -127.87 | -14.87 |
| Dividend Paid and CapEx Coverage Ratio | 0.17 | 0.01 | 0.40 | 0.70 | 0.87 |
| Capital Expenditure Coverage Ratio | 0.18 | 0.01 | 0.45 | 0.77 | 0.98 |
| Operating Cash Flow Coverage Ratio | 0.06 | 0.00 | 0.06 | 0.16 | 0.32 |
| Operating Cash Flow to Sales Ratio | 0.03 | 0.00 | 0.02 | 0.05 | 0.11 |
| Free Cash Flow Yield | -24.74% | -8.76% | -2.98% | -1.25% | -0.14% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | 756.23 | 32.05 | 68.00 | 399.37 | -34.29 |
| Price-to-Sales (P/S) Ratio | 0.52 | 0.62 | 0.93 | 1.24 | 1.51 |
| Price-to-Book (P/B) Ratio | 0.95 | 1.02 | 1.40 | 1.70 | 1.76 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -4.04 | -11.42 | -33.53 | -79.77 | -722.71 |
| Price-to-Operating Cash Flow Ratio | 18.48 | 997.22 | 41.75 | 24.08 | 14.30 |
| Price-to-Earnings Growth (PEG) Ratio | -7.87 | 0.57 | 0.18 | -3.69 | 0.19 |
| Enterprise Value Multiple | 15.38 | 10.93 | 15.87 | 23.63 | 73.43 |
| Enterprise Value | 257.19B | 236.01B | 273.71B | 302.01B | 309.30B |
| EV to EBITDA | 15.38 | 10.93 | 15.87 | 23.63 | 73.43 |
| EV to Sales | 0.97 | 0.99 | 1.27 | 1.54 | 1.81 |
| EV to Free Cash Flow | -7.55 | -18.12 | -45.37 | -98.79 | -869.78 |
| EV to Operating Cash Flow | 34.50 | 1582.70 | 56.50 | 29.82 | 17.21 |
| Tangible Book Value Per Share | 5929.65 | 5945.80 | 5887.01 | 5876.26 | 5954.15 |
| Shareholders’ Equity Per Share | 6092.18 | 6113.44 | 6039.29 | 6011.00 | 6094.48 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.59 | 0.05 | -0.37 | 1.99 | 0.25 |
| Revenue Per Share | 11062.88 | 9978.51 | 9049.96 | 8209.56 | 7138.48 |
| Net Income Per Share | 7.64 | 194.06 | 124.42 | 25.54 | -313.51 |
| Tax Burden | 0.41 | 0.95 | 1.37 | -0.99 | 0.75 |
| Interest Burden | 0.13 | 0.53 | 0.39 | -0.58 | 1.16 |
| Research & Development to Revenue | 0.07 | 0.02 | 0.02 | 0.02 | 0.03 |
| SG&A to Revenue | 0.22 | 0.20 | 0.17 | 0.12 | 0.11 |
| Stock-Based Compensation to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Income Quality | 69.00 | 0.03 | 1.63 | 16.59 | -2.40 |
Currency in KRW